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ABSTRACT 
 
Using proteomics analysis, we previously compared MCF7 breast cancer cells grown as 3D tumor spheres, with 
the same cell line grown as monolayers. Our results indicated that during 3D anchorage-independent growth, 
the cellular machinery associated with i) mitochondrial biogenesis and ii) ribosomal biogenesis, were both 
significantly increased. Here, for simplicity, we refer to these two new oncogenic hallmarks as “mito-stemness” 
and “ribo-stemness” features. We have now applied this same type of strategy to begin to understand how 
fibroblasts and MCF7 breast cancer cells change their molecular phenotype, when they are co-cultured 
together. We have previously shown that MCF7-fibroblast co-cultures are a valuable model of resistance to 
apoptosis induced by hormonal therapies, such as Tamoxifen and Fulvestrant. Here, we directly show that 
these mixed co-cultures demonstrate the induction of mito-stemness and ribo-stemness features, likely 
reflecting a mechanism for cancer cells to increase their capacity for accumulating biomass. In accordance with 
the onset of a stem-like phenotype, KRT19 (keratin 19) was induced by ~6-fold during co-culture. KRT19 is a 
well-established epithelial CSC marker that is used clinically to identify metastatic breast cancer cells in sentinel 
lymph node biopsies. The potential molecular therapeutic targets that we identified by label-free proteomics of 
MCF7-fibroblast co-cultures were then independently validated using a bioinformatics approach. More 
specifically, we employed publically-available transcriptional profiling data derived from primary tumor 
samples from breast cancer patients, which were previously subjected to laser-capture micro-dissection, to 
physically separate breast cancer cells from adjacent tumor stroma. This allowed us to directly validate that the 
proteins up-regulated in this co-culture model were also transcriptionally elevated in patient-derived breast 
cancer cells in vivo. This powerful approach for target identification and translational validation, including the 
use of patient outcome data, can now be applied to other tumor types as well, to validate new therapeutic 
targets that are more clinically relevant, for patient benefit. Moreover, we discuss the therapeutic implications 
of these findings for new drug development, drug repurposing and Tamoxifen-resistance, to effectively target 
mito-stemness and ribo-stemness features in breast cancer patients. We also discuss the broad implications of 
this “organelle biogenesis” approach to cancer therapy. 
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INTRODUCTION 
 
Cancer stem cells (CSCs) are now thought to be one 
of the major drivers behind treatment failure in many 
cancer types, including breast cancer [1]. As a con- 
sequence, residual CSCs, which are chemo-resistant 
and radio-resistant, result in tumor recurrence and 
distant metastasis, ultimately killing most cancer 
patients [2]. Therefore, there is an urgent need to 
understand what are the metabolic weak points within 
CSCs, to drive new drug discovery, for patient benefit. 
This requires new innovative approaches towards 
understanding “stemness” features and identifying 
specific metabolic targets in CSCs [3-5]. 
 
In order to identify new characteristic features of 
“stemness” in cancer cells, we previously compared 
the proteomic profiles of 3D-spheroid cultures of 
MCF7 breast cancer cells, with MCF7 monolayer 
cells, processed in parallel [6]. These 3D-spheroids 
were grown under anchorage-independent conditions 
and are also known as mammosphere cultures, which 
are highly enriched in CSCs and cancer progenitor 
cells [6]. Using this approach, we previously 
demonstrated that under these 3D growth conditions, 
MCF7 cells up-regulated the expression of >60 
mitochondrial-related proteins and >80 proteins 
related to protein synthesis, including ribosomal 
biogenesis [6,7]. Moreover, we have shown that 
pharmacologically targeting protein synthesis and/or 
mitochondrial function are both indeed sufficient to 
eradicate CSCs [8-14]. 
 
Here, we refer to these characteristic proteomic 
changes as “mito-stemness” [15] and “ribo-stemness”. 
We have now investigated whether these stemness 
features are also similarly up-regulated during the co- 
culture of MCF7 breast cancer cells with fibroblasts. 
Our current observations are consistent with the idea 
that MCF7-fibroblast co-cultures increase their 
biosynthetic cellular machinery, to expand their 
capacity to increase biomass. Therefore, “mito- 
stemness” and “ribo-stemness” features are actually 
oncogenic hallmarks of the ability and readiness of 
cancer cells to aggressively undergo biomass accumu-
lation. 
 
We also discuss the implications of our current 
findings for understanding and treating Tamoxifen-
resistance, as we have previously validated that the 
MCF7-fibroblast co-culture system is a bonafide 
model of Tamoxifen- resistance [16], which includes a 
stromal micro- environment, making it perhaps more 
physiologically- relevant. 
 
RESULTS 
 
Unbiased proteomics analysis: identification of 
proteins up-regulated in MCF7-fibroblast co- 
cultures 
 
Previously, we have demonstrated that cancer cells, 
grown in close proximity to fibroblasts, metabolically 
reprogram these fibroblasts towards a more catabolic 
state, via the induction of autophagy, mitophagy and 
glycolysis, as well as senescence [16-20]. Conversely, 
through this interaction, cancer cells undergo 
reciprocal metabolic reprogramming towards a more 
anabolic state, with the induction of mitochondrial 
biogenesis and oxidative metabolism [21,22]. This 
metabolic co-operation primarily benefits the cancer 
cells by providing nutrients to generate new biomass 
[17,18]. Unfortunately, most of the metabolic targets 
in this symbiotic process remain completely un- 
known. 
 
Here, we developed a new approach to identify these 
potential therapeutic targets, via unbiased proteomics 
analysis. For this purpose, we used MCF7 cells, an 
ER(+) human breast cancer cell line, as a model 
system. These MCF7 cells were co-cultured with 
hTERT-BJ1 fibroblasts, in a cellular ratio of 1:1, for a 
short 3-day period. These MCF7-fibroblast co-cultures 
were then directly compared to a 1:1 protein mixture 
of MCF7 cells and hTERT-fibroblasts, that had not 
been co- cultured together, but were grown instead as 
homotypic mono-cultures (Figure 1). 
 
To a first approximation, using proteomics, this 
approach should allow us to estimate and identify 
which proteins are increased during the co-culture 
process, relative to mono-cultures. Then, these protein 
candidates were compared with human breast cancer 
samples that had undergone laser-capture micro- 
dissection, to validate their relevant expression in 
human breast cancer cells in vivo. For this purpose, we 
used publicly-available transcriptional-profiling data 
(from N=28 breast cancer patients; See Materials and 
Methods). A diagram highlighting this work-flow is 
shown as Figure 2. 
 
Previously, we have shown that mitochondrial 
biogenesis in MCF7 cells is induced when they are 
co- cultured with fibroblasts [21,22]. However, it 
remains unknown exactly which mitochondrial 
proteins are induced during co-culture. Therefore, 
we focused first on which mitochondrial proteins 
were increased during co-culture, based on this 
proteomics approach. 
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Figure 1. Schematic diagram summarizing the work-flow for MCF7-fibroblast co-culture studies and bioinformatics 
validation. Protein lysates were obtained from hTERT-BJ1 fibroblasts after 72 h co-culture with MCF7 breast cancer cells. 
Alternatively, protein lysates were obtained from hTERT-BJ1 fibroblasts and MCF7 cells cultured separately as monolayers and then 
mixed. Peptides obtained after trypsin digestion were analysed via LC-MS/MS on an LTQ- Orbitrap XL mass spectrometer. Label-free 
quantitative proteomics was used to detect changes in protein abundances across co-cultures and mixed cell population extracts. The 
proteomics data sets were further analyzed using Ingenuity Pathway Analysis. This co-culture approach is predicted to better simulate 
the fibroblast-rich local tumor micro-environment in vivo. 
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Supplementary Table 1 illustrates the 45 mitochondrial- 
related proteins that were found to be significantly up- 
regulated during the MCF7-fibroblast co-culture 
process. This list includes proteins that are involved in 
mitochondrial biogenesis and/or are part of the 
mitochondrial complexes I to V, as well as mito-
chondrial chaperones, such as DNAJA3, HSPD1 and 
HSPA9, among others. Interestingly, NDUFAF2, a 
MYC-induced component of complex I [23], was 
infinitely up-regulated during co-culture. Interestingly, 
we have previously shown that the co-culture of MCF7 
cells with fibroblasts confers Tamoxifen-resistance, that 
is reversible by treatment with Metformin, a complex I 
inhibitor [16]. Therefore, NDUFAF2 (a.k.a, Mimitin 
[23]) may be functionally conferring Tamoxifen- 
resistance during co-culture. 
 
Since increased mitochondrial biogenesis is a hallmark 
of cancer stem cells (CSCs), known as “mito-stemess” 
[6-8,15], we next also looked for markers of protein 
synthesis [7], that is another hallmark of CSCs, which 
we now refer to here as “ribo-stemness”. Supplementary 
Table 2 shows that 28 components of the large and 
small cellular ribosomal subunits were up-regulated 
during co-culture. More specifically, 18 components of 
the large 60S ribosome and 10 components of the small 
40S ribosome were increased. Interestingly, RPL4 and 
RPS29 were infinitely increased during co-culture. 
 
Consistent with these findings, protein-folding 
chaperones were also induced. Supplementary Table 3 
lists 10 chaperones that were significantly increased 
during co-culture. These include members of the HSP90 
and HSP70 families of chaperones, as well as others. 
Remarkably, HSP90AB1 was infinitely up-regulated. 
 
Similarly, Supplementary Table 4 shows that proteins 
involved in mRNA translation initiation, polypeptide 
elongation, tRNA synthesis and amino acid uptake  
were all significantly up-regulated during co-culture. 
Overall, this includes 30 proteins in total. For example, 
EIF2S1, a translation initiation factor required for 
mRNA binding to ribosomes, was increased by nearly 
300-fold. 
 
Furthermore, other well-known markers of “stemness” 
and proliferation were increased, as shown in 
Supplementary Table 5. More specifically, MKI67 was 
 
 
Figure 2. Schematic diagram summarizing the work-flow for validation studies with transcriptional profiling data from 
clinical samples. Data from N=28 patient-derived breast primary tumor samples, which have been subjected to laser-capture 
micro-dissection, were used for validation. 
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increased by >4,000-fold, while KRT19 and PCNA 
were increased by nearly 6-fold and 4-fold, 
respectively. The profound increase in MKI67 is more 
consistent with increased protein synthesis, rather than 
increased proliferation. Interestingly, MKI67 is 
expressed in all cycling cells, except for resting cells in 
the G0-phase and is specifically associated with 
ribosomal RNA (rRNA) synthesis and, thus, protein 
synthesis. This is consistent with our results presented 
in Supplementary Tables 2-4. 
 
In this context, it is interesting to note that KRT19 is a 
well-established epithelial CSC marker that is used 
clinically to identify metastatic breast cancer cells in 
sentinel lymph node biopsies [24,25]. 
 
A summary of the proteins that were up-regulated by 
>100-fold is highlighted in Table 1. In conclusion, our 
current observations are consistent with the idea that 
MCF7-fibroblast co-cultures increase their biosynthetic 
cellular machinery (i.e., mitochondria and ribosomes), 
to expand their anabolic capacity to increase their 
biomass. 
 
Ingenuity pathway analysis (IPA) of MCF7- 
fibroblast co-cultures 
 
Differentially expressed proteins were also inde-
pendently analyzed using Ingenuity Pathway Analysis 
(IPA), to identify altered canonical pathways and 
toxicity functions. 
 
This analysis revealed that EIF2 signaling, which is 
crucial for protein synthesis, is a significantly 
activated canonical pathway in co-cultures, as 
compared to mono- cultures, as measured by a z-score 
Table 1. Proteomics summary: key targets that were up-regulated by >100-fold in MCF7-fibroblast co-
cultures. 
Gene Description Fold-increase 
     
1. Mitochondrial Proteins    
NDUFAF2 Mimitin, c-Myc-induced mitochondrial protein; B17.2L Infinity 
GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial  238.91 
AIFM1 Apoptosis-inducing factor 1, mitochondrial 237.74 
PRKDC DNA-dependent protein kinase catalytic subunit  102.78 
     
2. Ribosomal Proteins    
RPL4 60S ribosomal protein L4  Infinity 
RPS29 40S ribosomal protein S29  Infinity 
RPL15 60S ribosomal protein L15  2,238.12 
RPL19 60S ribosomal protein L19  168.84 
     
3. Chaperone and Translation 
 initiation factors    
HSP90AB1 
Heat Shock Protein 90kDa Alpha (Cytosolic), Class B Member 
1 Infinity 
EIF2S1 Eukaryotic translation initiation factor 2 subunit 1 291.47 
     
4. Ribosomal RNA (rRNA) 
synthesis    
MKI67 Antigen KI-67  4,531.38 
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> 2 (Figure 3). Other altered pathways and toxicity 
functions identified by IPA included mitochondrial 
dysfunction, NRF2- mediated oxidative stress, fatty 
acid metabolism, changes in mitochondrial membrane 
potential, HIF signaling, glutathione depletion, 
mitochondrial biogenesis, DNA-damage and fibrosis, 
among others (Figure 4). The observed similarity with 
renal injury appears to be related to an increase in 
oxidative stress and the resulting anti-oxidant 
response. 
 
Overall, these results are consistent with the induction 
of “mito-stemness” and “ribo-stemness” features, 
during the co-culture process. 
 
 
Figure 3. Ingenuity pathway analysis of differentially expressed proteins in co-cultures compared to mixed cell 
populations. Ingenuity Pathway Analysis (IPA) showed canonical pathways significantly altered (p < 0.001). The p value for each 
pathway is indicated by the bar and is expressed as -1 times the log of the p value. Red colored bars indicate a predicted significant 
activation of the pathway (z-score >2), whereas orange colored bars indicate a not significant activation (z-score between 0 and 2). 
Green bars indicate a not significant inhibition of the pathway (z-score between 0 and -2). White bars indicate that the pathway is 
altered, but it was not possible to predict whether it is activated nor inhibited. 
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Figure 4. “Toxicity” effects of differentially expressed proteins in co-cultures versus monocultures. Ingenuity Pathway 
Analysis showed toxicity functions significantly enriched by the proteins differentially expressed in co-cultures (p < 0.05). The p value 
for each pathway is indicated by the bar and is expressed as -1 times the log of the p value. 
 
 
 
Figure 5. A proteomics-based approach to the development of new breast cancer companion diagnostics, for 
predicting Tamoxifen-resistance. For this analysis, data from the proteomics analysis of MCF7- fibroblast co-cultures was 
intersected with clinical outcome data. More specifically, the clinical population we focused included ER(+) patients, of the luminal A 
sub-type, that were lymph-node positive (LN(+)) at diagnosis, who were treated with Tamoxifen and followed over nearly 200 
months. In this context, we ultimately evaluated the prognostic value of a mitochondrial signature for predicting tumor treatment 
failure (recurrence, metastasis or overall survival). 
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Validating the clinical relevance of co-culture 
proteomics data, using patient-derived breast tumor 
samples 
 
In order to directly validate the potential clinical 
relevance of our findings, we next used transcriptional 
profiling data derived from the analysis of N=28 breast 
cancer patients, which were previously subjected to 
laser-capture micro-dissection, to physically separate 
breast cancer cells from adjacent stromal cells [26].  
 
Therefore, we intersected our proteomics data, with this 
clinical data set, and the levels of fold-upregulation 
observed in the epithelial cancer cell compartment 
(relative to the tumor stroma), and corresponding p- 
values derived from these clinical samples, are shown in 
Supplementary Tables 6 to 9. 
 
Supplementary Table 6 shows that of the 45 mitochon-
drial proteins that were up-regulated during co-culture, 
34 were also significantly increased by >1.75-fold in 
human breast cancer cells in vivo. Therefore, >75% of 
the mitochondrial proteins elevated during co-culture 
were transcriptionally increased in patient-derived 
breast cancer cells in vivo. 
 
Similarly, Supplementary Table 7 highlights that of the 
28 ribosomal proteins that were up-regulated during co- 
culture, 27 were significantly increased by >1.7-fold in 
human breast cancer cells in vivo. Thus, >96% of the 
ribosomal proteins elevated during co-culture were 
transcriptionally increased in human breast cancer cells 
in vivo. 
 
In addition, Supplementary Table 8 illustrates that of  
 
the 10 chaperone proteins that were up-regulated during 
co-culture, 7 were significantly increased by >3.1-fold 
in human breast cancer cells in vivo. As such, 70% of 
the chaperone proteins increased during co-culture were 
also increased in human breast cancer cells. 
 
Finally, Supplementary Table 9 shows that of the 30 
proteins associated with mRNA translation initiation, 
polypeptide elongation, and tRNA synthesis, 19 were 
significantly increased by >1.7-fold in human breast 
cancer cells in vivo. As a result, >60% of these proteins 
were also increased in human breast cancer cells. 
 
Such a high concordance rate, between i) in vitro 
proteomics data and ii) in vivo human breast cancer 
transcriptional mRNA data, clearly validates the 
translational significance of the MCF7-fibroblast co- 
culture system, as a model for studying human breast 
cancer. 
 
Establishing new prognostic biomarkers and 
companion diagnostics for predicting tamoxifen- 
resistance, by exploiting proteomics data from 
MCF7-fibroblast co-cultures 
 
We have previously shown that the co-culture of MCF7 
cells with fibroblasts induces a Tamoxifen-resistance 
phenotype [16]. Therefore, to identify new potential 
biomarkers of Tamoxifen-resistance, here we 
intersected our proteomics data from MCF7-fibroblast 
co-cultures with publicly available transcriptional 
profiling data from the tumors of breast cancer patients 
that were treated with Tamoxifen, but did not receive 
any chemotherapy [27,28]. A schematic diagram 
summarizing this approach is shown in Figure 5. 
Table 2. Prognostic value of mitochondrial markers induced during metabolic symbiosis (MCF7-fibro) for 
tumor recurrence. 
Gene Probe ID Symbol Hazard-Ratio (RFS) Log-Rank Test     
211662_s_at VDAC2 3.96 6.70E-07 
200807_s_at HSPD1 3.46 1.30E-05 
200806_s_at HSPD1 2.34 0.005 
203633_at CPT1A 2.86 0.01 
203634_s_at CPT1A 2.32 0.025 
202698_x_at COX4I1 2.19 0.038 
211971_s_at LRPPRC 2.05 0.01 
200657_at SLC25A5 2.4 0.002 
221235_s_at TRAP1 1.77 0.048 
RFS: recurrence-free survival.  
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For this purpose, we selected high-risk patients that 
were lymph-node positive at diagnosis, and we focused 
on the luminal A subtype, which represents the most 
common form of ER(+) breast cancers (N = 152 
patients). The results of this analysis are shown in Table 
2. In this context, seven distinct mitochondrial genes, 
represented by 9 different gene probes, showed 
significant prognostic value, and were able to predict 
tumor recurrence. 
 
In order to increase the prognostic power of these 
individual mitochondrial biomarkers, we next selected 
the most promising ones and used them to create a new 
mitochondrial gene signature. This new Mito-Signature 
contains only 3 key genes (HSPD1, VDAC2, CPT1A) 
(Tables 3 and 4). K-M curves for this signature are 
shown in Figures 6 to 13. 
 
Importantly, this Mito-Signature yielded a 
significantly improved hazard-ratio for tumor 
recurrence of 5.52 (p = 7.3e-10). It was also highly 
predictive for distant metastasis, in the same group of 
patients (HR = 5.51; p = 8.1e-07). (See Figures 6). 
Similar results were obtained in Luminal A LN-
negative patients and Luminal B patients (Figure 7). 
 
We also examined the prognostic value of this 
mitochondrial gene signature in a larger group of ER(+) 
patients (N = 855), that received hormonal therapy, but 
not chemotherapy. This group of patients was not 
segregated into luminal A and luminal B subtypes. Figure 
8 shows the results of this K-M analysis for relapse-free 
survival (HR = 2.80; p = 8.7e-15). Similar results were 
also obtained distant metastasis-free survival (HR = 2.26; 
p = 3e-05; N = 548 patients). This mitochondrial signature 
was also effective if the ER(+) patient population was 
divided into LN(+) and LN(-) groups (Figure 9). 
 
Next, we assessed the behavior of this Mito-Signature 
in predicting overall survival. Figure 10 shows that it 
was also highly predictive of overall survival during 
hormonal therapy (HR = 3.06; p = 7.8e-05; N = 170 
patients). 
 
Moreover, Figure 11 shows that this Mito-Signature 
was also effective in all ER(+) breast cancer patients in 
predicting tumor recurrence (N = 3,082), as well as 
distant  metastasis  (N = 1,395). Similar results 
were obtained using data from all breast cancer patients, 
for recurrence (N = 3,951) and metastasis (N =1,746), 
as well as for post-progression survival (Figures 12 and 
13). Thus, this mitochondrial-based gene signature may 
represent an important new prognostic tool for 
predicting patient outcomes, in a wide variety of 
different breast cancer patients, but especially in ER(+) 
patients treated with hormonal therapies. 
Table 3. A 3-Gene mitochondrial signature for predicting treatment failure, due to tumor recurrence. 
Gene Probe ID Symbol Hazard-Ratio (RFS) Log-Rank Test 
    
211662_s_at VDAC2 3.96 6.70E-07 
200807_s_at HSPD1 3.46 1.30E-05 
203633_at CPT1A 2.86 0.01 
Combined  5.52 7.30E-10 
RFS: recurrence-free survival.  
 
Table 4. A 3-Gene mitochondrial signature for predicting treatment failure, due to distant metastasis. 
Gene Probe ID Symbol Hazard-Ratio (DMFS) Log-Rank Test 
    
211662_s_at VDAC2 3.11 0.0004 
200807_s_at HSPD1 3.5 9.70E-05 
203633_at CPT1A 2.79 0.026 
Combined  5.51 8.10E-07 
DMFS: distant metastasis-free survival.  
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Figure 7. K-M analysis of a Mito-Signature that shows predictive value in Luminal A (LN-negative) and Luminal B 
breast cancer patients, who were treated with hormonal therapy. Left, Luminal A/LN-negative (N = 394 patients; p 
=0.00023). Right, Luminal B (N = 275 patients; p = 5.4e-06). Patients with high-expression levels of the Mito- Signature showed a clear 
increase in recurrence, while being treated with hormonal therapy. RFS, recurrence-free survival. 
 
 
 
Figure 6. A three-gene based mitochondrial signature (Mito-Signature) that effectively predicts recurrence and distant 
metastasis in high-risk ER(+) breast cancer patients. Note that this Mito-Signature (HSPD1/VDAC2/CPT1A) predicts tumor 
recurrence (Left; N = 152 patients; p = 7.3e-10) and distant metastasis (Right; N = 149 patients; p = 8.1e-07) in LN(+) luminal A patients 
treated with Tamoxifen therapy, indicative of treatment failure and Tamoxifen-resistance. Patients with high-expression levels of the 
Mito-Signature showed a >5-fold increase in recurrence and distant metastasis, while being treated with hormonal therapy. See also 
Tables 3 and 4. RFS, reccurence-free survival; DMFS, distant metastasis-free survival. 
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Figure 8. K-M analysis of recurrence and metastasis using a Mito-Signature in a larger group of ER(+) breast cancer 
patients, who were treated with hormonal therapy. These patients were not sub-divided into luminal A/B subgroups and were 
not sub-divided by lymph-node status. Note that this Mito-Signature effectively predicts tumor recurrence (Left; N = 855 patients) 
and distant metastasis (Right; N = 548 patients). Patients with high- expression levels of the Mito-Signature showed a near 3-fold 
increase in recurrence (p = 8.7e-15) and a >2-fold increase in distant metastasis (p = 3e-05), while being treated with hormonal 
therapy. 
 
 
 
Figure 9. K-M analysis of recurrence using a Mito-Signature in a larger group of ER(+) breast cancer patients, that 
were divided into sub-groups by lymph node status, who were treated with hormonal therapy. These patients were not 
sub-divided into luminal A/B subgroups. Left, LN-positive (N = 235 patients). Right, LN-negative (N = 531 patients). Note that 
LN-positive patients with high-expression levels of the Mito-Signature showed a near 4-fold increase in recurrence, while being 
treated with hormonal therapy (p = 2.9 e-10). Similar results were observed in LN-negative patients, with a near 3-fold increase in 
recurrence (p = 1.7e-07). RFS, reccurence-free survival. 
 
www.aging-us.com 4812 AGING 
 
  
 
 
 
Figure 11. K-M analysis of recurrence and metastasis using a Mito-Signature in a larger group of all ER(+) breast 
cancer patients, independently of treatment. Patients with high-expression levels of the Mito-Signature showed near 2-fold 
increases in recurrence (N = 3,082; p < 1e-16) and distant metastasis (N = 1,395; p = 1.1e-07). 
 
 
 
 
Figure 10. K-M analysis of survival using a Mito-Signature in a group of ER(+) breast cancer. These patients were treated 
with hormonal therapy. Note that patients with high-expression levels of the Mito- Signature showed a >3-fold reduction in long-term 
survival (N = 170 patients; p = 7.8e-05). OS, overall survival. 
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Figure 13. K-M analysis of post-progression survival (PPS) using a Mito-Signature in ER(+) and all breast cancer 
patients, independently of treatment. Patients with high-expression levels of the Mito-Signature showed near 1.5-fold 
reductions in post-progression survival. Left, ER(+) (N = 313 patients; p = 0.01). Right, all breast cancer (N = 414 patients; p = 0.0055). 
 
 
 
 
Figure 12. K-M analysis of recurrence and metastasis using a Mito-Signature in a larger group of all breast cancer 
patients, independently of treatment. Patients with high-expression levels of the Mito-Signature showed near 2-fold increases 
in recurrence (N = 3,951; p < 1e-16) and distant metastasis (N = 1,746; p = 3.8e-08). 
 
www.aging-us.com 4814 AGING 
Markers of fibrosis and glycolysis are up-regulated 
in MCF7-fibroblast co-cultures, consistent with the 
onset of oxidative stress 
 
During the co-culture of fibroblasts with cancer cells, it 
has been observed that their phenotype is drastically 
changed [17,18]. These changes are related to the 
induction of various biological processes related 
oxidative stress, and are consistent with a more myo- 
fibroblastic phenotype [17,18]. These phenotypic 
changes include increased expression of cytoskeletal 
elements and glycolytic enzymes, as well as the 
elevation of markers of autophagy and senescence 
[18,21,22]. Therefore, we examined our proteomics data 
for evidence of these biological processes. 
 
Supplementary Table 10 illustrates that during MCF7- 
fibroblast co-cultures, many known markers of fibrosis 
and oxidative stress are actually increased. These 
changes include the up-regulation of 32 cytoskeletal and 
extracellular matrix proteins, 11 glycolytic enzymes, 4 
lysosomal/autophagy markers and 2 markers of the 
senescence-associated secretory phenotype, known as 
SASP. 
 
These findings are also consistent with our results from 
IPA analysis, shown in Figure 4. Therefore, our results 
potentially provide interesting new stromal targets for 
further validation in future studies. 
 
Validating the relevance of MCF7-fibroblast co- 
cultures for drug development, using FDA-approved 
antibiotics that target mitochondria 
 
Based on our current findings, we observed that 45 
mitochondrial proteins were significantly increased 
during the co-culture of stromal fibroblasts, with MCF7 
cancer cells (Supplementary Table 1). This is consistent 
with our previous studies employing the vital fluo-
rescent dye MitoTracker, showing that mitochondrial 
mass is dramatically increased during MCF7-fibroblasts 
co-cultures [21,22]. This may also have implications for 
drug sensitivity to mitochondrial inhibitors, especially 
those targeting mitochondrial biogenesis. 
 
To directly test this hypothesis, we developed an assay 
system to monitor the sensitivity of cancer cells to drug 
treatment, in the presence or absence of fibroblasts. For 
this purpose, we generated hTERT-BJ1-fibroblasts 
expressing RFP (red fluorescent protein) and MCF7 
cells expressing GFP (green fluorescent protein). 
Representative images of these mono-cultures are 
shown in Figure 14. 
 
As positive controls for this assay system, we employed 
two FDA-approved antibiotics (Doxycycline and 
Azithromycin), which have been shown to act as 
inhibitors of mitochondrial biogenesis, because of the 
long-standing evolutionary relationship between 
mitochondria and bacteria [8,9]. Doxycycline and 
Azithromycin both inhibit mitochondrial protein 
translation, as off-target “side-effects”, by preferentially 
affecting the mitochondrial ribosome. 
 
As predicted, Doxycycline preferentially targeted 
MCF7-GFP cells, during their co-culture with fibro- 
blasts, as directly compared with MCF-GFP mono- 
cultures (Figure 15). Quantitation of cellular GFP fluo-
rescence was performed using a plate-reader, at the 
appropriate wavelength (See Materials and Methods). 
At 500 µM Doxycycline, MCF7-GFP cells in co- 
culture were ~5-fold more sensitive, than those in 
mono-cultures. However, the increased sensitivity of 
MCF7-GFP cells in co-culture was first observed at 100 
 
 
Figure 14. Representative images of hTERT-fibroblasts and MCF7 cells expressing fluorescent proteins. 
hTERT-BJ1-fibroblasts expressing RFP and MCF7 cells expressing GFP were generated by lentiviral transduction. RFP, red fluorescent 
protein; GFP, green fluorescent protein. 
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µM, but not at 50 µM. Doxycycline also begins to 
inhibit overall protein synthesis in mammalian cells, in 
the range of 100 µM to 1 mM [29]. However, this effect 
is likely secondary to mitochondrial ATP- depletion 
(IC-50 = 50 µM) [30]. Therefore, Doxycycline may 
effectively target both “mito-stemness” and “ribo-
stemness” features, by inhibiting both i) mitochondrial 
protein synthesis and ii) overall protein synthesis. 
Representative images of these MCF7-fibroblast co- 
cultures and their differential sensitivity to Doxycycline 
are shown in Figure 16. Note the progressive reductions 
in GFP-fluorescence. 
 
Quantitatively similar results were obtained with 
Azithromycin, another well-established inhibitor of 
mitochondrial biogenesis (Figure 17). Azithromycin 
 
 
Figure 15. Doxycycline preferentially targets MCF7-GFP cells, during co-culture with fibroblasts: Bar graphs. Note that 
mono-cultures of MCF7-GFP cells are quantitatively more resistant to the killing effects of Doxycycline, as the concentration of 
Doxycycline is progressively increased, from 50 µM to 5 mM. Note that at 500 µM Doxycycline, MCF7-GFP cells in co-culture are 
~5-fold more sensitive, than those in mono-cultures. 
 
 
 
Figure 16. Doxycycline preferentially targets MCF7-GFP cells, during co-culture with fibroblasts: Fluorescence 
micrographs. Note that as the concentration of Doxycycline is progressively increased, from 250 µM to 1 mM, the green fluorescent 
signal is decreased. 
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preferentially targeted MCF7-GFP cells, in co-culture 
with fibroblasts. At 500 µM Azithromycin, MCF7-GFP 
cells in co-culture were ~8-fold more sensitive, than 
those in mono-cultures. 
 
These pharmacological data (representing enhanced 
sensitivity to mitochondrial protein translation 
inhibitors) are consistent with the increases in mito-
chondrial biogenesis that we observed by proteomics 
analysis in MCF7-fibroblast co-cultures. 
 
DISCUSSION 
 
Here, we have used MCF7-fibroblast co-cultures as a 
model system to dissect the molecular basis of 
Tamoxifen-resistance. Previously, we showed that 
MCF7-fibroblasts co-cultures are protected against 
apoptosis induced by hormonal therapies, such as 
Tamoxifen and Fulvestrant [16], and that this resistance 
could be reversed by using Metformin, a known 
mitochondrial inhibitor [16]. Metformin acts as an 
OXPHOS inhibitor and activates AMP-kinase, by 
functionally inactivating mitochondrial Complex I 
activity. However, the molecular targets that confer 
resistance to hormonal therapy in this epithelial-stromal 
model have remained elusive, although it was noted that 
mitochondrial mass was increased in MCF7 cells, as 
seen by vital staining with the probe MitoTracker 
[21,22]. 
To identify potential new therapeutic targets, we 
subjected this co-culture system to unbiased label-free 
proteomics analysis. Using this approach, we observed 
the induction of both “mito-stemness” and “ribo- 
stemness” features, consistent with the induction of a 
more stem-like phenotype (Figure 18). In further 
support of this notion, the epithelial CSC marker 
KRT19 was induced nearly 6-fold. KRT19 is currently 
used clinically to identify metastatic breast cancer cells 
in sentinel lymph-node biopsies [24,25]. 
 
The specific candidate targets identified by proteomics 
analysis were then intersected with a wealth of 
publically-available clinical data, first to validate their 
expression in human breast cancer cells in vivo. These 
clinical samples were subjected to laser-capture micro- 
dissection to separate human breast cancer cells, from 
adjacent tumor stroma, before they were subjected to 
mRNA-based transcriptional profiling. 
 
Unfortunately, we cannot rule out that some of the 
protein products that we observed were up-regulated in 
the MCF7-fibroblast co-cultures, were simply due to 
cancer cell proliferation. Nevertheless, these candidates 
were further intersected with transcriptional profiling 
data derived from human breast cancer samples, 
providing independent cell-type specific validation for 
their clinical relevance. Therefore, this approach 
provides an effective workflow to generate new 
 
 
Figure 17. Azithromycin preferentially targets MCF7-GFP cells, during co-culture with fibroblasts: Bar graphs. Note that 
mono-cultures of MCF7-GFP cells are quantitatively more resistant to the killing effects of Azithromycin, as the concentration of 
Azithromycin is progressively increased, from 50 µM to 5 mM. Note that at 500 µM Azithromycin, MCF7-GFP cells in co-culture are 
~8-fold more sensitive, than those in mono-cultures. 
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candidate targets and a means for their clinical 
validation. 
 
To assess whether these candidate biomarkers could be 
used as companion diagnostics for Tamoxifen- 
resistance, we used the targets identified by proteomics 
to construct a mitochondrial gene signature. Then, using 
publically-available clinical outcome data, we strin-
gently evaluated the prognostic value of this Mito- 
Signature, which effectively predicted tumor recurrence 
and distant metastasis in breast cancer patients that were 
treated with Tamoxifen or hormonal therapy. The 
development of recurrence or metastasis during 
Tamoxifen treatment is a clear sign of treatment failure 
and is an accepted clinical hallmark of Tamoxifen- 
resistance. 
 
We next assessed a possible treatment strategy to 
selectively sensitize MCF7 cells in co-culture, based on 
their apparent increase in mitochondrial biogenesis. For 
this purpose, we devised a co-culture system employing 
fluorescently-labeled MCF7 cells and fibroblasts. In this 
system, MCF7 cells expressing GFP were co- cultured 
with hTERT-BJ1 fibroblasts expressing RFP, so that 
these two cellular components were easily 
distinguishable. 
 
We hypothesized that certain FDA-approved antibiotics 
that target host protein synthesis and mitochondrial 
protein translation as off-target side effects might be 
able to sensitize MCF7 cells, under co-culture 
conditions. Interestingly, our results indicate that MCF7 
cells in co-culture were ~5-fold more sensitive to the 
effects of Doxycycline and ~8-fold more sensitive to the 
effects of Azithromycin. Therefore, the targeting of 
mitochondrial protein translation via drug repurposing 
may be an effective anti-cancer strategy, especially 
under these more physiologically-relevant culture 
 
 
Figure 18. An “organelle biogenesis” approach to cancer therapy. A schematic diagram illustrating that breast cancer cells in 
co-culture increase their “mito-stemness” and “ribo-stemness” features is shown. Note the increases in mitochondrial biogenesis and 
the protein synthesis machinery, as enumerated in Supplementary Tables 1 to 4 and independently confirmed by Ingenuity Pathway 
Analysis (IPA). These findings predict increased susceptibility to treatment with FDA-approved antibiotics, such as Doxycycline and 
Azithromycin.  
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conditions, which includes a stromal tumor-micro-
environment. 
 
Other recent studies using mono-cultures of MCF7 cells 
have also suggested a role for increased mitochondrial 
OXPHOS, in conferring Tamoxifen-resistance. For 
example, Tamoxifen-resistant MCF7 cells, derived from 
long-term cell culture with increasing concentrations of 
Tamoxifen, showed an increase in mitochondrial mass 
and mitochondrial-dependent ATP production [31]. 
Similarly, over-expression of a somatic mutation of the 
estrogen receptor (ESR1-Y537S) normally associated 
with the clinical development of Tamoxifen-resistance 
in patients, also increased mitochondrial mass and 
mitochondrial-dependent ATP production [32]. There- 
fore, three independent models of Tamoxifen-resistance 
mechanistically appear to show the same or a very 
similar mitochondrial phenotype. 
 
As such, this highly-suggestive data implies that 
mitochondrial inhibitors should be tested clinically as a 
possible therapeutic option for the prevention and/or 
treatment of Tamoxifen-resistance or perhaps other 
forms of hormonal therapy resistance. 
 
In this context, it is interesting to note that one of the 
recognized off-target side effects of Tamoxifen is that it 
behaves as a bonafide inhibitor of mitochondrial 
complex III and complex IV [33], while simultaneously 
inducing oxidative stress. Therefore, Tamoxifen 
treatment itself may lead to drug resistance, simply by 
stimulating mitochondrial biogenesis in response to its 
own intrinsic anti-mitochondrial activity, rather than via 
its direct or targeted effects on ER-alpha signaling. It is 
interesting to also consider these anti-mitochondrial 
effects of Tamoxifen, given the proposed metabolic 
etiology of breast cancer pathogenesis, related to 
mitochondrial biogenesis [34,35]. 
 
In summary, we conclude that the observed increases in 
“organelle biogenesis” (i.e., mitochondria and 
ribosomes) may represent new metabolic hallmarks of a 
more aggressive cancer cell phenotype. We propose that 
these findings can be exploited to design more broadly- 
applicable therapeutics and predictive companion 
diagnostics, to target stemness features in multiple 
cancer types. Our results highlight the potential clinical 
utility of this “organelle biogenesis” approach to cancer 
therapy (Figure 18). 
 
MATERIALS AND METHODS 
 
Cell culture 
 
Cell culture experiments were carried out using human 
skin fibroblasts immortalized with the human 
telomerase reverse transcriptase (hTERT-BJ1 cells) and 
human MCF7 breast cancer cells. hTERT-BJ1 
fibroblasts and MCF7 cells were maintained in 
complete media: DMEM (D6546, Sigma) supplemented 
with 10% fetal bovine serum (F7524, Sigma), 100 
units/ml of penicillin, 100 μg/ml, streptomycin (P0781, 
Sigma) and 1% Glutamax (#35050087, Life 
Technologies). For all experiments, cells were 
incubated at 37°C in a humidified atmosphere 
containing 5% CO2. 
 
Co-culture versus mixed cell populations 
 
MCF7 cells and fibroblasts were co-cultured in the 
presence of Nu-Serum, essentially as we previously 
described [16-18]. Two million MCF7 cells were co-
cultured in a regular 15 cm dish with two million 
hTERT-BJ1 fibroblasts, seeded in a 1:1 ratio. Likewise, 
the same numbers of either MCF7 cells or hTERT-BJ1 
fibroblasts were seeded separately in 15 cm dishes as 
monocultures. After 72h of cell culture cells were lysed 
in RIPA lysis buffer (R0278, Sigma) containing 
proteinase inhibitors (05 892 970 001, Roche) and kept 
at 4° C for 20 minutes with rotation. Lysates were 
cleared by centrifugation for 10 minutes at 10,000 x g 
and supernatants were collected. The protein 
concentration of the lysates was determined by using 
the BCA protein assay kit (23225, Pierce). Briefly, four 
µg of MCF7- hTERT-BJ1 co-culture lysate or two µg of 
hTERT-BJ1 monoculture lysate mixed with 2 µg of 
MCF7 monoculture protein lysate (4 µg of protein in 
total) were submitted to the CRUK Proteomics Core 
Facility, for label-free proteomic analysis. Proteomics 
and statistical analyses were carried out on a fee-for-
service basis by Dr. Duncan Smith and his colleagues, 
at the Proteomics Core Facility at the Cancer Research 
UK Manchester Institute, University of Manchester. 
 
Label-free proteomics analysis 
 
Chemicals and sample preparation 
Formic acid, trifluoroacetic acid, ammonium formate 
(10 M), ammonium bicarbonate TCEP (Tris (2- 
carboxyethyl)phosphine hydrochloride), MMTS 
(Methyl methanethiosulfonate) and trypsin were all 
obtained from Sigma. HPLC gradient grade acetonitrile 
was obtained from Fisher Scientific. 
 
Protein digestion 
Lysate samples were thawed to room temperature and 
their concentrations equalised to 1 μg/μL (50 μL 
volume) with RIPA buffer, and further processed for 
trypsin digestion by sequential reduction of disulphide 
bonds with TCEP and alkylation with MMTS. Briefly, 1 
μL benzonase (Novagen) was added to the 50 μL 
aliquot and placed on ice for 15 minutes. The sample 
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was then taken to dryness using a SpeedVac, and 
resuspended in 22.5 μL trypsin reaction buffer (40 mM 
ammonium bicarbonate and 9% acetonitrile). One μL of 
50 mM TCEP solution was added to each sample, 
mixed briefly and placed on a heater block at 60°C for 
60 minutes. After cooling to room temperature, 0.5 μL 
of 200 mM MMTS solution was added to each sample 
and allowed to react for 15 minutes. Trypsin was added 
in two waves to ensure efficient digestion of the sample. 
Firstly, 20 μg of sequencing grade trypsin was resus- 
pended in 1800 μL of trypsin reaction buffer; 225 μL of 
this solution were added to each sample for digestion, 
and the reactions were left at 37°C overnight with 
shaking (600 rpm). The following morning, a further 
aliquot of trypsin was added. Two ml of trypsin reaction 
buffer was added to 20 μL of sequencing grade trypsin; 
250 μL of this solution were added to each of the digest 
samples from overnight, and the reactions were left at 
37°C for 4 hours with shaking (600 rpm). Thirty-five 
μL 10% formic acid were added to the 500 μL digest 
sample (0.7% final concentration of formic acid) to stop 
the digestion. The digested solution was diluted in 7.5 
mL of acetonitrile containing 0.3% formic acid. 
 
HILIC solid phase extraction (SPE) of peptides 
PolyhydroxyethylA SPE 12 μm, 300A, 300 mg 
cartridges (obtained from PolyLC) were used for the 
HILIC procedure. Prior to use, cartridges required an 
overnight soak in 50 mM formic acid followed by 
rinsing with water the following day. Cartridges were 
preconditioned with 2 mL of Buffer A (90% 
acetonitrile, 5 mM ammonium formate, pH 2.7) fol- 
lowed by 2 mL of Buffer B (5 mM ammonium formate, 
pH 2.7) and finally re-equilibrated with 10 mL Buffer 
A. The diluted samples were loaded onto the cartridges 
and washed with a further 10 mL Buffer A. Finally, 
peptides were eluted in 1 mL Buffer C (9 parts Buffer B 
plus 1 part Buffer A) and the samples dried on a 
Speedvac to remove organic solvent prior to LCMS/MS 
analysis. 
 
LC-MS/MS analysis 
Lyophilized digests were resuspended in 50 μL of 0.1% 
TFA to give an approximate concentration of 1 μg/μL. 
One μL injection volumes were used throughout 
resulting in an on-column peptide loading of 
approximately 1 μg per injection. Analysis was per- 
formed in quintuplicate for each sample type. All LC- 
MS/MS analyses were performed on an LTQ Orbitrap 
XL mass spectrometer coupled to an Ultimate 3000 
RSLCnano system (Thermo Scientific). One μL 
injection volumes were used throughout and samples 
loaded directly onto the analytical column, PepMap 
RSLC C18, 2 μm × 75 μm id × 50 cm (Thermo 
Scientific). The composition (v/v) of LC buffers were as 
follows; Buffer A - 99.9% water plus 0.1% formic acid 
and Buffer B - 80% acetonitrile, 19.9% water and 0.1% 
formic acid. Peptides were loaded directly onto the 
column at a flow rate of 400 nl/min with an initial 
mobile phase composition of 1% B. The organic 
strength was increased linearly from 1% to 22.5% B 
over 22.5 minutes again at 400 nl/min, followed by an 
increase to 24.8% B over the next 2.6 minutes with a 
concomitant reduction in flow rate to 300 nl/min, and to 
39% B over a further 14 minutes. A further increase to 
60% B over the next 5 minutes was followed by a ramp 
to 95% B over 2.5 minutes where it was held for a 
further 2 minutes. The column was then allowed to re- 
equilibrate to 1% B for a total analysis time of 74 
minutes. The mass spectrometer was instructed to 
perform data dependent acquisition on the top six 
precursor ions, which were measured in the Orbitrap 
FTMS detector over the mass range 370–1200 m/z, at a 
nominal resolution of 60,000. MS/MS spectra were 
acquired in the ion trap under CID conditions with 
normalized collision energy of 35, isolation width of 3 
Th, Q value of 0.25 and 30 ms activation time. Gas- 
phase fractionation was performed on the five replicate 
injections such that MS/MS data was collected for 
precursor ion range 370–494 m/z Injection 1, 494–595 
m/z Injection 2, 595–685 m/z Injection 3, 685–817 m/z 
Injection 4 and 817–1200 m/z Injection 5. 
 
Statistical analysis 
Xcalibur raw data files acquired on the LTQ-Orbitrap 
XL were directly imported into Progenesis LCMS 
software (Waters Corp) for peak detection and 
alignment. Data were analysed using the Mascot search 
engine. Five replicates were analysed for each sample 
type. Statistical analyses were performed using 
ANOVA and only fold-changes in proteins with a p- 
value less than 0.05 were considered significant. 
 
Ingenuity pathway analyses 
Pathway and function analyses were generated using 
Ingenuity Pathway Analysis (IPA) (Ingenuity systems, 
http://www.ingenuity.com), which assists with 
proteomics data interpretation via grouping 
differentially expressed genes or proteins into known 
functions and pathways. Pathways with a z score > 1.9 
were considered as significantly activated, and 
pathways with a z score < −1.9 were considered as 
significantly inhibited. 
 
Validation with transcriptional profiling of breast 
cancer patient samples 
 
To directly establish the clinical relevance of our 
findings from proteomics analysis of MCF7-fibroblast 
co-cultures, we re-analyzed the publically-available 
transcriptional profiles [26] of epithelial breast cancer 
cells and adjacent tumor stromal cells that were 
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physically separated by laser-capture microdissection 
(from N=28 human breast cancer patients). 
 
Validation with Kaplan-Meier (K-M) analyses of 
breast cancer patient samples 
 
To perform K-M analysis of mitochondrial gene 
transcripts, we used an open-access online survival 
analysis tool to interrogate publically available 
microarray data from up to 3,455 breast cancer patients 
[27]. This allowed us to determine their prognostic 
value [28]. For this purpose, we primarily analyzed data 
from ER(+) patients that were LN(+) at diagnosis and 
were of the luminal A sub-type, that were primarily 
treated with Tamoxifen and not other chemotherapy 
(N=152 patients). In this group, 100% the patients 
received some form of hormonal therapy and ~95% of 
them received Tamoxifen. Biased and outlier array data 
were excluded from the analysis. This allowed us to 
identify mitochondrial gene transcripts, with significant 
prognostic value. Hazard-ratios were calculated, at the 
best auto-selected cut-off, and p- values were calculated 
using the logrank test and plotted in R. K-M curves 
were also generated online using the K-M-plotter (as 
high-resolution TIFF files), using univariate analysis:  
 
http://kmplot.com/analysis/index.php?p=service&cance
r=breast 
 
This allowed us to directly perform in silico validation 
of these mitochondrial biomarker candidates. The multi- 
gene classifier function of the program was used to test 
the prognostic value of short mitochondrial gene 
signatures, using the mean expression of the selected 
probes. 
 
Validation via drug treatment of fluorescently- 
labeled MCF7-fibroblast co-cultures 
 
hTERT-BJ1-RFP cells and MCF7-GFP cells were first 
generated by stable transduction with lenti-viral vectors. 
Then, these cells were plated into clear flat bottom 96- 
well black microplates (Corning; CLS3603). Mono- 
cultures were generated by plating either hTERT-BJ1- 
RFP (8,000 cells/well) or MCF7-GFP cells (8,000 
cells/well). In parallel, co-cultures were generated by 
co-plating hTERT-BJ1-RFP (6,000 cells/well) with 
MCF7-GFP (2,000 cells/well). The next day, the plates 
were treated with either Doxycycline or Azithromycin 
(or vehicle controls) and were incubated for 72 hours at 
37oC. The cell culture plates were then read with a 
plate-reader at 545/590 nm (for RFP) and at 
490/510 nm (for GFP). Background readings were 
subtracted from the fluorescent signal and data were 
then normalized to controls. 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Tables 
 
 
Supplementary Table 1. Proteomics Analysis: Mitochondrial-Related Proteins Up-regulated in MCF7-Fibroblast Co-Cultures.  
 
Gene Symbol Description           Fold-Increase Mito-Complex MRP/Chaperone 
 
NDUFAF2  Mimitin, c-Myc-induced mitochondrial protein; B17.2L (related to NDUFAF4/HRPAP20)  Infinity  I   Chaperone 
GPD2  Glycerol-3-phosphate dehydrogenase, mitochondrial (ROS/H2O2 Production)   238.91 
AIFM1   Apoptosis-inducing factor 1, mitochondrial (NADH oxidase activity)    237.74  I, III, IV   Chaperone 
PRKDC  DNA-dependent protein kinase catalytic subunit  (mitochondrial genome maintenance)  102.78 
DNAJA3 HSP40, DnaJ homolog, subfamily A, member 3, mitochondrial      76.43     Chaperone 
MRPL43 Mitochondrial ribosomal protein L43         66.38    MRP 
COX4I1 Cytochrome c oxidase subunit 4 isoform 1        56.68   IV   
HSPD1  HSP60, 60 kDa heat shock protein, mitochondrial       29.29                               Chaperone  
MRRF   Ribosome-recycling factor, mitochondrial        23.53     MRP 
SLC25A5  Solute Carrier Family 25 (Mitochondrial Carrier; ADP/ATP Translocator), Member 5   14.49 
VDAC2  Voltage-dependent anion-selective channel protein 2       13.60 
UQCRFS1  RISP, Ubiquinol-cytochrome C reductase iron-sulfur subunit, (Rieske iron-sulfur protein)   13.07   III 
VDAC1  Voltage-dependent anion-selective channel protein 1       10.05 
ECH1  Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial      8.51 
MCCC2 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial      4.52 
MRPS28  MRPS28 protein           3.86     MRP 
ATP5A1  ATP synthase subunit alpha, mitochondrial (EC 3.6.3.14)      3.83  V 
SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial      3.58 
ABAT   4-aminobutyrate aminotransferase, mitochondrial       3.44 
IMMT  Mitochondrial inner membrane protein         3.27 
AK4   Adenylate kinase isoenzyme 4, mitochondrial        3.02 
GOT2  Aspartate aminotransferase, mitochondrial        2.87 
HSPA9  heat shock 70kDa protein 9 (mortalin), mitochondrial      2.47     Chaperone 
TUFM   Elongation factor Tu, mitochondrial         2.37 
CLUH  Clustered mitochondria protein homolog        2.15 
OAT   Ornithine aminotransferase, mitochondrial        2.14 
IDH1   Isocitrate dehydrogenase [NADP], cytoplasmic        2.10 
SLC25A3 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3    2.09 
NDUFA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5    2.08  I 
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial       2.07   III 
ETFA   Electron transfer flavoprotein subunit alpha, mitochondrial      2.05 
PPA2   Inorganic pyrophosphatase 2, mitochondrial        2.03 
ECHS1  Enoyl-CoA hydratase, mitochondrial         2.02 
PPT1   Palmitoyl-protein thioesterase 1          1.91 
www.aging-us.com 4825 AGING 
DLD  Dihydrolipoyl dehydrogenase, mitochondrial        1.89 
CHCHD3 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial    1.89 
ATP5H   ATP synthase subunit d, mitochondrial         1.88   V 
IARS2  Isoleucine--tRNA ligase, mitochondrial         1.86 
LRPPRC  Leucine-rich PPR-motif containing, mitochondrial       1.85 
PC   Pyruvate carboxylase, mitochondrial         1.79 
HADHA  Trifunctional enzyme subunit alpha, mitochondrial       1.74 
SLC25A13 Calcium-binding mitochondrial carrier protein Aralar2       1.74  
TRAP1  Heat shock protein 75 kDa, mitochondrial        1.72     Chaperone 
ACADSB  Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial     1.72 
CPT1A   Carnitine palmitoyltransferase 1A, mitochondrial        1.65 
 
 
-Proteins listed above (45 in total) were all upregulated in MCF7-Fibroblast Co-cultures (p <0.05). MRP, mitochondrial ribosomal proteins 
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Supplementary Table 2. Proteomics Analysis: Ribosomal Proteins Up-regulated in MCF7-Fibroblast Co-
Cultures.  
 
Gene Symbol Description    Fold-Increase  
 
RPL4  60S ribosomal protein L4   Infinity 
RPL15   60S ribosomal protein L15   2,238.12 
RPL19  60S ribosomal protein L19   168.84 
RPL36AL 60S ribosomal protein L36a-like  54.47 
RPL24  60S ribosomal protein L24   43.56 
RPL10   60S ribosomal protein L10   42.78 
RPL29  60S ribosomal protein L29   20.53 
RPL18A 60S ribosomal protein L18a   17.08 
RPL8  60S ribosomal protein L8   5.74 
RPL34  60S ribosomal protein L34   5.36 
RPL13  60S ribosomal protein L13   5.31 
RPL14  60S ribosomal protein L14   3.09 
RPL3  60S ribosomal protein L3   3.04 
RPL27a  60S ribosomal protein L27a   2.99 
RPLP2  60S acidic ribosomal protein P2  2.90 
RPL6  60S ribosomal protein L6   2.05 
RPL5  60S ribosomal protein L5   2.04 
RPL28  60S ribosomal protein L28  2.00 
 
RPS29  40S ribosomal protein S29   Infinity 
RPS10  40S ribosomal protein S10   74.47 
RPS6  40S ribosomal protein S6   23.37 
RPS18  40S ribosomal protein S18   9.20 
RPS27A  40S ribosomal protein S27a   5.19 
RPS2  40S ribosomal protein S2   2.98 
RPS27A  40S ribosomal protein S27a   2.96 
RPS3A  40S ribosomal protein S3A   2.39 
RPS19  40S ribosomal protein S19   2.05 
RPS11  40S ribosomal protein S11  2.00 
 
-Proteins listed above (28 in total) were all upregulated in MCF7-Fibroblast Co-cultures (p <0.05). 
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Supplementary Table 3. Proteomics Analysis: Other Chaperones Up-regulated in MCF7-Fibroblast Co-
Cultures.  
 
Gene Symbol Description        Fold-Increase  
 
HSP90AB1  Heat Shock Protein 90kDa Alpha (Cytosolic), Class B Member 1  Infinity 
HSPA5  78 kDa glucose-regulated protein      82.18 
HSP90AA1  Heat Shock Protein 90kDa Alpha (Cytosolic), Class A Member 1  79.52 
HSPB1  Heat Shock 27kDa Protein 1      35.73 
HSPA8  Heat shock cognate 71 kDa protein      8.42 
HSPA4  Heat shock 70 kDa protein       5.38 
STIP1  Stress-induced-phosphoprotein 1 (HSP70/HSP90-organizing protein)  2.99 
CDC37  HSP90 co-chaperone Cdc37       2.83 
HSPA2  Heat shock-related 70 kDa protein 2      2.59 
HSPH1  Heat shock protein 105 kDa       2.53 
 
 
-Proteins listed above (10 in total) were all upregulated in MCF7-Fibroblast Co-cultures (p <0.05). 
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Supplementary Table 4. Proteomics Analysis: Proteins Involved in mRNA Translation Initiation, 
Polypeptide Elongation, tRNA Synthesis and Amino Acid Uptake are All Up-regulated in MCF7-Fibroblast 
Co-Cultures.  
 
Gene Symbol Description         Fold-Increase  
 
Translation initiation factors (required for mRNA binding to ribosomes) 
EIF2S1  Eukaryotic translation initiation factor 2 subunit 1     291.47 
EIF3H   Eukaryotic translation initiation factor 3 subunit H    81.05 
EIF4H   Eukaryotic translation initiation factor 4H      31.21 
EIF4A1  Eukaryotic translation initiation factor 4A-I      18.85 
EIF5   Eukaryotic translation initiation factor 5      8.72 
EIF3A   Eukaryotic translation initiation factor 3 subunit A    2.94 
EIF2S3L  Putative eukaryotic translation initiation factor 2 subunit 3-like protein   2.86 
EIF3E  Eukaryotic translation initiation factor 3 subunit E     2.30 
EIF3B   Eukaryotic translation initiation factor 3 subunit B     1.85 
 
Elongation factors (promote delivery of aminoacyl tRNAs to the ribosome) 
EEF2  Elongation factor 2        18.96 
EEF1G  Elongation factor 1-gamma        2.45 
TUFM   Elongation factor Tu, mitochondrial       2.37 
EEF1A2 Elongation factor 1-alpha 2        2.36 
EEF1A1 Elongation factor 1-alpha        2.03 
EEF1D  Elongation factor 1-delta        1.86 
 
Enzymes for tRNA Synthesis 
QARS   Glutamine--tRNA ligase, cytoplasmic      31.90 
DARS   Aspartate--tRNA ligase, cytoplasmic       9.69 
MARS   Methionine-tRNA synthetase, cytoplasmic     3.44 
RTCB  tRNA-splicing ligase RtcB homolog (C22orf28)      3.25 
DTD1  D-tyrosyl-tRNA(Tyr) deacylase 1       3.10 
YARS   Tyrosine--tRNA ligase, cytoplasmic       2.38 
RARS   Arginine--tRNA ligase, cytoplasmic       2.23 
AARS  Alanyl-tRNA synthetase, cytoplasmic      2.23 
IARS2  Isoleucine--tRNA ligase, mitochondrial      1.86 
AIMP2  Aminoacyl tRNA synthase complex-interacting multifunctional protein 2   1.70 
GARS   Glycine--tRNA ligase, cytoplasmic      1.70 
EPRS   Bifunctional glutamate/proline--tRNA ligase      1.67 
TRMT112 tRNA methyltransferase 112 homolog       1.66 
 
Amino Acid Transporters 
SLC6A19  Neutral amino acid transporter B(0)       4.18 
SLC7A5  Solute carrier family 7 (Cationic AA transporter, y+ system), member 5   3.05 
 
 
-Proteins listed above (30 in total) were all upregulated in MCF7-Fibroblast Co-cultures (p <0.05). 
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Supplementary Table 5. Proteomics Analysis: Markers of Cell Proliferation and Stemness are Up-regulated 
in MCF7-Fibroblast Co-Cultures. 
 
Gene 
Symbol 
Description Fold-
Increase 
Specificity 
MKI67 Antigen KI-67 4,531.38 Expressed in all cycling cells, except for resting 
cells in the G0-phase; Associated also with 
ribosomal RNA (rRNA) synthesis and, thus, 
protein synthesis 
KRT19 Keratin, type I 
cytoskeletal 19 
5.94 Marker of CSCs and breast cancer metastasis 
(sentinel lymph node) 
PCNA Proliferating cell nuclear 
antigen 
3.87 Marker for the G1/S phase of the cell cycle 
 
 
-Proteins listed above were upregulated in MCF7-Fibroblast Co-cultures (p <0.05). 
-In human breast cancer cells in vivo, KRT19 was transcriptionally up-regulated by 4.39-fold (p=2.66E-05), 
relative to the adjacent tumor stroma. Similarly, PCNA levels were up-regulated by 3.58-fold (p=3.64E-04).
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Supplementary Table 6. Nuclear Mitochondrial Gene Transcripts Up-regulated in Human Breast Cancers 
(Cancer Epithelia vs. Tumor Stroma). 
 
Gene Symbol   Fold-Increase   P-Value 
 
UQCRFS1   5.71    2.45E-07 
MCCC2   5.48    5.78E-07 
ATP5A1   5.01   3.09E-06 
UQCRC2   4.84   5.73E-06 
IMMT    4.71   8.89E-06 
IARS2    4.70   9.15E-06 
GOT2    4.58   1.40E-05 
LRPPRC   4.34   3.15E-05 
ECHS1   4.05   8.22E-05 
ATP5H    4.01   9.48E-05 
VDAC2   3.99    0.0001 
DLD   3.78    0.0002 
PPT1    3.76   0.0002 
SLC25A3   3.76   0.0002 
HSPA9   3.69   0.0002 
SLC25A5   3.49    0.0005 
HSPD1   3.42    0.0006 
COX4I1   3.39   0.0007 
TUFM    3.38   0.0007 
HADHA   3.27   0.0009 
PPA2    3.19    0.001 
IDH1    3.18    0.001 
OAT    3.17   0.001 
SUCLG2   3.03   0.002 
DNAJA3   2.92   0.003 
NDUFA5   2.75   0.004 
CHCHD3   2.74   0.004 
SLC25A13   2.69   0.005 
VDAC1   2.64    0.005 
MRPS28   2.25   0.01 
PRKDC   2.14   0.02  
ABAT    2.08   0.02 
ECH1    1.97    0.03 
ETFA    1.75    0.04 
 
-Transcriptional profiling data derived from the analysis of N=28 breast cancer patients are shown, high-lighting the 
levels of fold-upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and 
corresponding p-values derived from the analysis of these clinical samples.  
 
-Proteins listed above (34 in total) were all upregulated in MCF7-Fibroblast Co-cultures (Compare with 
Supplementary Table 1) (p <0.05). 
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Supplementary Table 7. Ribosomal Protein Gene Transcripts Up-regulated in Human Breast Cancers 
(Cancer Epithelia vs. Tumor Stroma). 
 
Gene Symbol   Fold-Increase   P-Value 
 
RPL24    5.38   8.11E-07 
RPL3   5.01   3.14E-06 
RPL10    4.91   4.48E-06 
RPL15    4.60   1.28E-05 
RPL13    4.48   1.98E-05 
RPL14   4.45   2.15E-05 
RPL6   4.00   9.86E-05 
RPL19    3.98   0.0001 
RPL8    3.86    0.00015 
RPLP2    3.80    0.0002 
RPL34    3.63    0.0003 
RPL4    3.05    0.002 
RPL29    2.94    0.002 
RPL27A  2.87   0.003 
RPL5   2.74   0.004 
RPL28   2.33   0.01 
RPL18A   2.28    0.01 
RPL36AL   1.70   0.048 
 
RPS18    4.96   3.71E-06 
RPS27A   4.63   1.19E-05 
RPS3A   4.59   1.35E-05 
RPS6    4.47   2.04E-05 
RPS10    4.18   5.34E-05 
RPS19   4.17   5.49E-05 
RPS11   3.58   0.0004 
RPS2   3.36   0.0007 
RPS29    2.31   0.01 
 
 
-Transcriptional profiling data derived from the analysis of N=28 breast cancer patients are shown, high-lighting the 
levels of fold-upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and 
corresponding p-values derived from the analysis of these clinical samples.  
 
-Proteins listed above (27 in total) were all upregulated in MCF7-Fibroblast Co-cultures (Compare with 
Supplementary Table 2). (p <0.05). 
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Supplementary Table 8. Other Chaperone Gene Transcripts Up-regulated in Human Breast Cancers (Cancer 
Epithelia vs. Tumor Stroma). 
 
Gene Symbol   Fold-Increase   P-Value 
 
HSP90AB1   4.93   4.03E-06 
HSPA5   3.89   0.0001 
HSP90AA1   3.76   0.0002 
HSPA4   3.75   0.0002 
HSPB1   3.27   0.001 
HSPH1   3.18   0.001 
HSPA8   3.11   0.002 
 
 
-Transcriptional profiling data derived from the analysis of N=28 breast cancer patients are shown, high-lighting the 
levels of fold-upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and 
corresponding p-values derived from the analysis of these clinical samples.  
 
-Proteins listed above (7 in total) were all upregulated in MCF7-Fibroblast Co-cultures (Compare with 
Supplementary Table 3). (p <0.05). 
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Supplementary Table 9. Transcripts of Genes Associated with mRNA Translation Initiation, Polypeptide 
Elongation, and tRNA Synthesis Are All Up-regulated in Human Breast Cancers (Cancer Epithelia vs. 
Tumor Stroma). 
 
Gene Symbol   Fold-Increase   P-Value 
 
Translation initiation factors (required for mRNA binding to ribosomes)  
EIF4H    4.77   7.20E-06 
EIF3H    4.70   9.25E-06  
EIF5    3.90   0.0001 
EIF3E   3.57   0.0004  
EIF3A    2.51   0.008   
EIF3B    2.21   0.02 
 
Elongation factors (promote delivery of aminoacyl tRNAs to the ribosome) 
EEF2   4.01   9.29E-05  
EEF1G   3.71    0.0002  
TUFM    3.38    0.0007   
EEF1A1   3.16    0.001 
EEF1D   2.50    0.008 
 
Enzymes for tRNA Synthesis 
IARS2   4.70   9.15E-06 
RTCB   4.59   1.37E-05 
MARS    4.35   3.00E-05 
EPRS     4.06   8.10E-05 
QARS    3.73    0.0002 
DARS     3.43    0.0006 
DTD1   1.78    0.04 
YARS     1.72    0.046   
 
 
-Transcriptional profiling data derived from the analysis of N=28 breast cancer patients are shown, high-lighting the 
levels of fold-upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and 
corresponding p-values derived from the analysis of these clinical samples.  
-Proteins listed above (19 in total) were all upregulated in MCF7-Fibroblast Co-cultures (Compare with 
Supplemental Table 4). (p <0.05). 
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Supplementary Table 10. Proteomics Analysis: Stromal CAF Markers are Up-regulated in MCF7-Fibroblast 
Co-Cultures 
 
Gene Symbol Description      Fold-Increase  
 
Glycolytic Enzymes  
PKM   Pyruvate kinase      Infinity 
LDHA  L-Lactate dehydrogenase A     426.16 
PGD  6-Phosphogluconate dehydrogenase, decarboxylating  13.59 
ENO1  Alpha-Enolase       11.60 
ALDOA  Fructose-bisphosphate aldolase    7.14 
PGI  Glucose-6-phosphate isomerase    5.02 
PFK  6-Phosphofructokinase      4.14 
PGK1  Phosphoglycerate kinase 1     4.38 
TPI1  Triosephosphate isomerase 1     2.66 
G6PD  Glucose-6-phosphate 1-dehydrogenase   2.28 
  
Cytoskeletal and Extracellular Matrix Proteins 
MYH9  Myosin Heavy Chain 9     226.32 
COL4A1 Collagen Type IV Alpha 1 Chain    211.46 
CTTN  Cortactin       202.50 
DNHD1  Dynein heavy chain domain-containing protein 1  195.80 
NEFL  Neurofilament light polypeptide     124.55 
FLNA   Filamin-A       60.54 
KIF5C  Kinesin heavy chain isoform 5C     60.34 
TLN1  Talin-1        33.25 
S100P  S100 Calcium Binding Protein P    21.23 
SPTAN1 Spectrin alpha chain, non-erythrocytic 1    11.78 
MYH11  Myosin Heavy Chain 11     8.99 
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1    8.51 
COL1A1 Collagen Type I Alpha 1 Chain     7.38 
CFL1  Cofilin-1       6.36 
MYO18B  Myosin XVIIIB       6.11 
PLEC1  Plectin 1, intermediate filament binding protein   5.48 
SRRM2  Serine/arginine repetitive matrix protein 2  5.18 
S100A16 S100 Calcium Binding Protein A16    4.87 
SRRM1  Serine/arginine repetitive matrix protein 1   4.77 
ACTN2  Alpha-actinin-2       4.31 
MAP4  Microtubule-associated protein     4.22 
DNM2  Dynamin-2       4.10 
ARPC1B  Actin related protein 2/3 complex, subunit 1B   3.43 
MACF1  Microtubule-actin cross-linking factor 1    3.26 
VCL   Vinculin       2.66 
TPM4   Tropomyosin alpha-4      2.65 
ANKRD12 Ankyrin repeat domain-containing protein 12   2.58 
VIL2  Villin 2 (Ezrin)       2.57 
DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2   2.42 
VIM  Vimentin       2.37 
NEFM  Neurofilament medium polypeptide    2.35 
TUBB3  Tubulin beta-3      2.35 
 
Senescence and the SASP (Senescence-Associated Secretory Phenotype) 
HMGB2 High mobility group protein B2     64.01 
HMGB21 High mobility group protein B1     4.00 
 
Autophagy/Lysosomal Markers 
ATP6V1E1 ATPase, H+ transporting, lysosomal, V1 subunit E1  2.60 
ATP6V1A V-type proton ATPase catalytic subunit A   2.56 
CTSD   Cathepsin D       2.08 
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CTSZ  Cathepsin Z       2.07 
 
___________________________________________________________________________________________ 
 
-Proteins listed above were all upregulated in MCF7-Fibroblast Co-cultures (p <0.05). 
 
